Deschatelets Pascal Insider Trading Activity (APLS)

Profile

Pascal Deschatelets is a biotechnology executive who, according to the most recent SEC filing dated 2026-01-15, held the role of Chief Scientific Officer at Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on complement system inhibitors. In this context, Deschatelets’ responsibilities include overseeing scientific strategy and translational research programs at Apellis.

Role	Insider
Notability	35/100

Board memberships

Apellis Pharmaceuticals, Inc.

Awards & honors

Led scientific strategy for Apellis' complement inhibitor programs
Oversaw translational research and early clinical development planning
Contributed to the advancement of C3-targeted therapeutic discovery

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	25.8K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	11.3K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	3.4K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	4.9K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	25.8K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	25.8K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	12.9K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	12.9K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	10.0K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	10.0K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	41.2K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	41.2K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	J — Other acquisition / disposition	1.18M	—
2026-01-30	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	25.8K	$0.00
2026-01-23	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	5.9K	$21.77	$129K
2026-01-21	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	909	$19.79	$18K
2026-01-15	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	2.3K	$22.19	$51K

Frequently Asked Questions

Who is Deschatelets Pascal?

How many SEC Form 4 filings has Deschatelets Pascal submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has Deschatelets Pascal been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 3 open-market sales ($198K) across all tracked filings.

Where can I see all of Deschatelets Pascal's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Deschatelets Pascal — SEC Form 4 Insider Trading Activity

Summary